Enovis Corporation (NYSE:ENOV – Get Free Report) Director Sharon Wienbar bought 900 shares of the stock in a transaction that occurred on Wednesday, November 11th. The shares were bought at an average price of $27.76 per share, for a total transaction of $24,984.00. Following the completion of the transaction, the director directly owned 45,551 shares of the company’s stock, valued at $1,264,495.76. This represents a 2.02% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.
Enovis Stock Performance
NYSE:ENOV traded down $0.92 during mid-day trading on Thursday, hitting $27.63. 1,153,270 shares of the company traded hands, compared to its average volume of 1,886,113. The stock’s fifty day moving average price is $20.36 and its 200-day moving average price is $23.19. Enovis Corporation has a one year low of $16.70 and a one year high of $31.81. The company has a quick ratio of 1.08, a current ratio of 2.15 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -3.00 and a beta of 1.31.
Enovis (NYSE:ENOV – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The business had revenue of $558.73 million during the quarter, compared to analysts’ expectations of $557.12 million. During the same quarter in the prior year, the business posted $0.75 earnings per share. The business’s quarterly revenue was up 1.8% on a year-over-year basis. Research analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Enovis
Several large investors have recently made changes to their positions in the business. First Trust Advisors LP raised its stake in Enovis by 60.2% during the 3rd quarter. First Trust Advisors LP now owns 100,117 shares of the company’s stock valued at $1,829,000 after purchasing an additional 37,636 shares during the period. Public Sector Pension Investment Board lifted its holdings in Enovis by 66.0% in the 3rd quarter. Public Sector Pension Investment Board now owns 328,148 shares of the company’s stock worth $6,223,000 after purchasing an additional 130,436 shares in the last quarter. Intech Investment Management LLC lifted its holdings in Enovis by 477.1% in the 3rd quarter. Intech Investment Management LLC now owns 70,796 shares of the company’s stock worth $1,293,000 after purchasing an additional 58,528 shares in the last quarter. Maryland State Retirement & Pension System bought a new position in Enovis in the 3rd quarter worth approximately $238,000. Finally, Illinois Municipal Retirement Fund boosted its stake in Enovis by 22.4% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 38,366 shares of the company’s stock worth $701,000 after purchasing an additional 7,028 shares during the period. 98.45% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research firms recently issued reports on ENOV. UBS Group reissued a “buy” rating and issued a $44.00 target price on shares of Enovis in a report on Monday, October 5th. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 2nd. Needham & Company LLC lifted their price target on shares of Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, November 5th. BMO Capital Markets set a $27.00 price target on shares of Enovis in a research report on Tuesday, September 1st. Finally, Wells Fargo & Company increased their price objective on shares of Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.62.
View Our Latest Report on Enovis
About Enovis
Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.
Further Reading
- Five stocks we like better than Enovis
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
